SALTS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHY-DRO-5H-PYRROLO[3,4-B]PYRAZINE
Novel mesylate, (R)-mandelate, succinate, citrate, fumarate, D-malate, D-tartrate, sulfate and L-tartrate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.
1 . A salt of zopiclone chosen from a mesylate, (R)-mandelate, succinate, citrate, fumarate, D-malate, D-tartrate, sulfate and L-tartrate salt.
2 . A salt of eszopiclone chosen from a mesylate, (R)-mandelate, succinate, citrate, fumarate, D-malate, D-tartrate, sulfate and L-tartrate salt.
3 . A salt according to claim 1 of formula
4 . A salt according to claim 2 of formula
5 . A salt according to claim 1 of formula
6 . A salt according to claim 2 of formula
7 . A salt according to claim 1 of formula
8 . A salt according to claim 2 of formula
9 . A salt according to claim 1 of formula
10 . A salt according to claim 2 of formula
11 . A salt according to claim 1 of formula
12 . A salt according to claim 2 of formula
13 . A salt according to claim 1 of formula
14 . A salt according to claim 2 of formula
15 . A salt according to claim 1 of formula
16 . A salt according to claim 2 of formula
17 . A salt according to claim 1 of formula
18 . A salt according to claim 2 of formula
19 . A salt according to claim 1 of formula
20 . A salt according to claim 2 of formula
21 . A pharmaceutical dosage form comprising the salt of claim 1 and a pharmaceutically acceptable carrier.
22 . A composition formed by reacting racemic or enantioenriched 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine and an acid chosen from methanesulfonic acid, (R)-mandelic acid, succinic acid, citric acid, fumaric acid, D-malic acid, D-tartartic acid, L-tartaric acid and sulfuric acid.
23 .- 31 . (canceled)